Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Net Income (2022 - 2025)

Historic Net Income for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' Net Income rose 2689.24% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 2619.57%. This contributed to the annual value of -$287.2 million for FY2024, which is 2005.45% down from last year.
  • Latest data reveals that Axsome Therapeutics reported Net Income of -$47.2 million as of Q3 2025, which was up 2689.24% from -$47.9 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Net Income peaked at -$11.2 million during Q1 2023, and registered a low of -$98.6 million during Q4 2023.
  • Over the past 4 years, Axsome Therapeutics' median Net Income value was -$61.2 million (recorded in 2022), while the average stood at -$57.9 million.
  • In the last 5 years, Axsome Therapeutics' Net Income surged by 7164.41% in 2023 and then tumbled by 50826.66% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Net Income (Quarter) stood at -$61.2 million in 2022, then plummeted by 61.06% to -$98.6 million in 2023, then grew by 24.05% to -$74.9 million in 2024, then surged by 36.95% to -$47.2 million in 2025.
  • Its Net Income was -$47.2 million in Q3 2025, compared to -$47.9 million in Q2 2025 and -$59.4 million in Q1 2025.